+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Doxorubicin Market - Global Forecast 2026-2032- Product Image
Doxorubicin Market - Global Forecast 2026-2032- Product Image
Sale

Doxorubicin Market - Global Forecast 2026-2032

  • Report

  • 187 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6082554
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Doxorubicin Market is projected to reach USD 1.17 Billion in 2026. It is expected to continue growing at a CAGR of 6.31%, reaching USD 1.69 Billion by 2032.

Doxorubicin remains one of the most clinically important anthracycline chemotherapy agents, with broad use across breast cancer, ovarian cancer, bladder cancer, lymphomas, leukemias, sarcomas, and several pediatric malignancies. Its continued relevance is anchored in decades of oncology evidence, inclusion on the World Health Organization Model List of Essential Medicines, and established roles in multi-drug chemotherapy regimens where tumor response, curative intent, and cost-effectiveness remain central purchasing criteria.

Demand for doxorubicin is shaped by the global cancer burden, which the International Agency for Research on Cancer estimated at approximately 20 million new cancer cases and 9.7 million cancer deaths in 2022. At the same time, the market is becoming more specialized as hospitals, cancer centers, and procurement agencies balance conventional doxorubicin hydrochloride injection with pegylated and non-pegylated liposomal doxorubicin formulations designed to alter pharmacokinetics and reduce selected toxicity risks.

Transformative Shifts in the Doxorubicin Landscape

The doxorubicin landscape is shifting from volume-driven generic chemotherapy toward formulation differentiation, resilient supply, and precision supportive care. Conventional doxorubicin remains essential because it is widely available and embedded in guideline-supported protocols, while liposomal doxorubicin has gained strategic importance in settings where modified tissue distribution, reduced peak plasma exposure, and improved tolerability profiles can influence treatment selection.

Another major shift is the growing focus on cardiotoxicity management. Doxorubicin’s cumulative dose-related risk of cardiomyopathy, commonly associated with lifetime exposure thresholds around 450-550 mg/m² depending on patient risk factors and regimen, has made baseline cardiac assessment, echocardiographic monitoring, biomarker use, and cardioprotective strategies increasingly important. This is pushing oncology providers to integrate cardio-oncology services into cancer treatment pathways.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to affect the doxorubicin value chain from discovery through clinical operations. In research settings, AI-supported modeling is used to analyze tumor biology, drug sensitivity patterns, combination therapy opportunities, and mechanisms of anthracycline resistance. These applications can help prioritize studies involving doxorubicin combinations with targeted therapies, immunotherapies, and novel delivery technologies.

In clinical practice and market access, AI can support patient risk stratification by integrating electronic health records, cardiac imaging, laboratory values, and prior treatment exposure. For manufacturers and distributors, predictive analytics can improve demand forecasting, inventory allocation, pharmacovigilance signal detection, and shortage risk monitoring for injectable oncology medicines, where manufacturing complexity and sterile fill-finish constraints can disrupt continuity of care.

Key Regional Insights for Doxorubicin

Asia-Pacific is a high-priority region for doxorubicin due to rising cancer incidence, expanding oncology infrastructure, and large patient populations in China, India, Japan, South Korea, Australia, and ASEAN markets. China and India are especially important for generic oncology manufacturing and domestic treatment access, while Japan, South Korea, and Australia maintain mature regulatory systems, established hospital oncology networks, and higher adoption of advanced formulations and cardiac monitoring practices.

North America remains a premium doxorubicin market supported by comprehensive oncology guidelines, high diagnostic capacity, cancer-center density, and strong uptake of branded, generic, and liposomal formulations. Europe benefits from centralized and national reimbursement pathways, with EU member states emphasizing quality-assured generics, pharmacovigilance, hospital procurement efficiency, and evidence-based use of liposomal doxorubicin. Latin America shows growing need for essential chemotherapy access, particularly in Brazil and Mexico, although public reimbursement constraints and tender-based purchasing influence availability. The Middle East, led by GCC healthcare investment, is strengthening oncology infrastructure and centralized procurement, while Africa continues to prioritize access to essential cancer medicines amid workforce, financing, diagnostic, and cold-chain limitations.

Key Group Insights Across Global Blocs

ASEAN countries are expanding oncology capacity through public hospital networks, universal health coverage initiatives, and increased access to essential cancer medicines, making affordability and dependable supply central to doxorubicin adoption. GCC markets are shaped by high healthcare spending, centralized procurement, and rising cancer-center investment, creating demand for quality-certified injectable chemotherapy, liposomal formulations, and robust distribution systems.

The European Union is driven by harmonized quality expectations, pharmacovigilance, and health technology assessment discipline, while BRICS countries represent substantial treatment demand because of population scale, cancer burden, domestic manufacturing capacity, and ongoing expansion of public oncology services. G7 markets remain influential for clinical standards, regulatory expectations, oncology innovation, liposomal delivery, and cardio-oncology protocols. NATO countries, many of which overlap with G7 and EU markets, place additional emphasis on supply security, medicine resilience, sterile injectable availability, and strategic healthcare preparedness for critical oncology drugs.

Key Country Insights for Doxorubicin

The United States is defined by advanced oncology practice, strong guideline influence, established use of anthracycline-based regimens, and close monitoring of injectable drug shortages, making supplier reliability and quality compliance key differentiators. Canada emphasizes public reimbursement, evidence-based access, provincial procurement, and equitable oncology care delivery, while Mexico and Brazil are important Latin American markets where public-sector purchasing, private oncology expansion, and access to quality-assured generics shape doxorubicin utilization.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine mature oncology systems with cost-containment pressure that favors quality-assured generics and clinically justified liposomal use. Germany and France maintain strong specialist oncology networks and rigorous reimbursement evaluation, the United Kingdom emphasizes evidence-led treatment pathways, while Italy and Spain balance regional procurement with broad hospital oncology access. Russia maintains domestic pharmaceutical priorities and public oncology programs, although geopolitical and supply-chain factors influence access dynamics.

China and India are central to treatment volume and manufacturing scale, with cancer burden, local production, pricing policy, and expanding hospital oncology services strongly affecting market structure. Japan, South Korea, and Australia are mature Asia-Pacific markets with high regulatory standards, advanced cancer care, and stronger adoption of supportive monitoring practices for anthracycline-related cardiotoxicity. South Korea and Japan also support sophisticated hospital-based chemotherapy delivery, while Australia’s reimbursement and clinical governance systems reinforce evidence-based doxorubicin use.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize supply resilience, sterile manufacturing quality, and transparent capacity planning because doxorubicin is an essential oncology drug where shortages can directly affect treatment schedules. Dual sourcing of active pharmaceutical ingredients, validated backup manufacturing sites, robust quality systems, and proactive communication with hospital purchasing groups can strengthen market position.

Manufacturers should also invest in differentiated formulations, real-world evidence, pharmacovigilance, and cardio-oncology partnerships. Demonstrating reduced toxicity burden, predictable pharmacokinetics, reliable availability, and practical administration advantages can support formulary inclusion, while education on cumulative dose monitoring, cardiac risk assessment, and risk mitigation can improve clinician confidence and patient outcomes.

Research Methodology

This executive summary is built from secondary research using authoritative oncology, regulatory, and public health sources, including global cancer statistics, medicine essentiality frameworks, drug labeling principles, clinical guideline concepts, and established pharmacology literature on anthracyclines. The analysis emphasizes verified therapeutic use, regional access patterns, formulation trends, toxicity management, and supply-chain considerations rather than unsupported market-size claims.

Insights were structured using a market intelligence framework that assesses demand drivers, clinical adoption, regulatory maturity, procurement behavior, manufacturing risk, pharmacovigilance requirements, and regional healthcare capacity. Country and group-level interpretation was developed by comparing oncology infrastructure, reimbursement mechanisms, population scale, cancer care delivery, and availability of quality-assured injectable chemotherapy.

Conclusion

Doxorubicin continues to be a cornerstone chemotherapy agent because it combines broad antitumor activity, guideline relevance, essential-medicine status, and established use in curative and palliative oncology regimens. The market is mature but not static; formulation innovation, toxicity management, AI-enabled analytics, and supply resilience are redefining competitive advantage.

Organizations that can deliver reliable access, quality manufacturing, evidence-based differentiation, and region-specific commercialization strategies will be best positioned. As cancer incidence rises globally, the doxorubicin market will remain strategically important across both high-income oncology systems and emerging markets seeking affordable, effective, and clinically trusted cancer treatment.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Doxorubicin Market, by Drug Type
7.1. Introduction
7.2. Branded Doxorubicin
7.3. Generic Doxorubicin
8. Doxorubicin Market, by Drug Formulation
8.1. Introduction
8.2. Liposomal Injection
8.2.1. Non Pegylated Liposomal
8.2.2. Pegylated Liposomal
8.3. Lyophilized Powder
9. Doxorubicin Market, by Route of Administration
9.1. Introduction
9.2. Intravenous
9.2.1. Bolus Injection
9.2.2. Infusion
9.3. Intravesical
10. Doxorubicin Market, by Dosage Strength
10.1. Introduction
10.2. 10 mg
10.3. 20 mg
10.4. 50 mg
10.5. 100 mg
11. Doxorubicin Market, by Cancer Type
11.1. Introduction
11.2. Breast Cancer
11.3. Lymphoma
11.3.1. Hodgkin Lymphoma
11.3.2. Non Hodgkin Lymphoma
11.4. Leukemia
11.4.1. Acute Lymphoblastic Leukemia
11.4.2. Acute Myeloid Leukemia
11.5. Bladder Cancer
11.6. Kaposi Sarcoma
11.7. Ovarian Cancer
11.8. Kidney Cancer
11.9. Liver Cancer
12. Doxorubicin Market, by End User
12.1. Introduction
12.2. Ambulatory Surgical Centers
12.3. Hospitals
12.3.1. Public Hospitals
12.3.2. Private Hospitals
12.4. Research Institutes
12.5. Specialty Cancer Centers
13. Doxorubicin Market, by Distribution Channel
13.1. Introduction
13.2. Offline
13.3. Online
14. Doxorubicin Market, by Region
14.1. Asia-Pacific
14.2. Europe
14.3. North America
14.4. Latin America
14.5. Africa
14.6. Middle East
15. Doxorubicin Market, by Group
15.1. NATO
15.2. G7
15.3. BRICS
15.4. European Union
15.5. ASEAN
15.6. GCC
16. Doxorubicin Market, by Country
16.1. China
16.2. United States
16.3. Japan
16.4. India
16.5. Germany
16.6. United Kingdom
16.7. Australia
16.8. France
16.9. South Korea
16.10. Italy
16.11. Canada
16.12. Russia
16.13. Brazil
16.14. Mexico
16.15. Spain
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. Apotex Inc.
18.2. Baxter International Inc.
18.3. Cadila Pharmaceuticals Ltd.
18.4. Cipla Limited
18.5. Dr. Reddy's Laboratories Limited
18.6. Fresenius Kabi AG
18.7. Getwell Oncology Pvt Ltd.
18.8. Glenmark Pharmaceuticals Ltd.
18.9. Hikma Pharmaceuticals PLC
18.10. Johnson & Johnson Services Inc.
18.11. Manus Aktteva Biopharma LLP
18.12. Meiji Holdings Co., Ltd.
18.13. Pfizer Inc.
18.14. Sun Pharmaceutical Industries Ltd.
18.15. Teva Pharmaceutical Industries Ltd.
18.16. TTY Biopharma Company Limited
List of Figures
FIGURE 1. GLOBAL DOXORUBICIN MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL DOXORUBICIN MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL DOXORUBICIN MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL DOXORUBICIN MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL DOXORUBICIN MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL DOXORUBICIN MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL DOXORUBICIN MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL DOXORUBICIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL DOXORUBICIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL DOXORUBICIN MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2032 (%)
FIGURE 13. GLOBAL DOXORUBICIN MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL DOXORUBICIN MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL DOXORUBICIN MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL DOXORUBICIN MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL DOXORUBICIN MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 19. GLOBAL DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL DOXORUBICIN MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL DOXORUBICIN MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL DOXORUBICIN MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL DOXORUBICIN MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL DOXORUBICIN MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL DOXORUBICIN MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL DOXORUBICIN MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL DOXORUBICIN MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL DOXORUBICIN MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL DOXORUBICIN MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL DOXORUBICIN MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL BRANDED DOXORUBICIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL BRANDED DOXORUBICIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL BRANDED DOXORUBICIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL GENERIC DOXORUBICIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL GENERIC DOXORUBICIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL GENERIC DOXORUBICIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL LIPOSOMAL INJECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL LIPOSOMAL INJECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL LIPOSOMAL INJECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL NON PEGYLATED LIPOSOMAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL NON PEGYLATED LIPOSOMAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL NON PEGYLATED LIPOSOMAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL PEGYLATED LIPOSOMAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL PEGYLATED LIPOSOMAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL PEGYLATED LIPOSOMAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL DOXORUBICIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL BOLUS INJECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL BOLUS INJECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL BOLUS INJECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL INFUSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL INFUSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL INFUSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL INTRAVESICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL INTRAVESICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL INTRAVESICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL DOXORUBICIN MARKET SIZE, BY DOSAGE STRENGTH, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL 10 MG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL 10 MG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL 10 MG MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL 20 MG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL 20 MG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL 20 MG MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL 50 MG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL 50 MG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL 50 MG MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL 100 MG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL 100 MG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL 100 MG MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL DOXORUBICIN MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL LYMPHOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL LYMPHOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL LYMPHOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL HODGKIN LYMPHOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL HODGKIN LYMPHOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL HODGKIN LYMPHOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL NON HODGKIN LYMPHOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL NON HODGKIN LYMPHOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL NON HODGKIN LYMPHOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL LEUKEMIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL LEUKEMIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL LEUKEMIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL ACUTE MYELOID LEUKEMIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL ACUTE MYELOID LEUKEMIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL ACUTE MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL BLADDER CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL BLADDER CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL BLADDER CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL OVARIAN CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL OVARIAN CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL KIDNEY CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL KIDNEY CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL KIDNEY CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL LIVER CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL LIVER CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL LIVER CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL DOXORUBICIN MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL SPECIALTY CANCER CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL SPECIALTY CANCER CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL SPECIALTY CANCER CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL DOXORUBICIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2017-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2017-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY DOSAGE STRENGTH, 2017-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 126. EUROPE DOXORUBICIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. EUROPE DOXORUBICIN MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 128. EUROPE DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2017-2032 (USD MILLION)
TABLE 129. EUROPE DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2017-2032 (USD MILLION)
TABLE 130. EUROPE DOXORUBICIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 131. EUROPE DOXORUBICIN MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 132. EUROPE DOXORUBICIN MARKET SIZE, BY DOSAGE STRENGTH, 2017-2032 (USD MILLION)
TABLE 133. EUROPE DOXORUBICIN MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 134. EUROPE DOXORUBICIN MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 135. EUROPE DOXORUBICIN MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 136. EUROPE DOXORUBICIN MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 137. EUROPE DOXORUBICIN MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 138. EUROPE DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 139. NORTH AMERICA DOXORUBICIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 140. NORTH AMERICA DOXORUBICIN MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 141. NORTH AMERICA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2017-2032 (USD MILLION)
TABLE 142. NORTH AMERICA DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2017-2032 (USD MILLION)
TABLE 143. NORTH AMERICA DOXORUBICIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 144. NORTH AMERICA DOXORUBICIN MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 145. NORTH AMERICA DOXORUBICIN MARKET SIZE, BY DOSAGE STRENGTH, 2017-2032 (USD MILLION)
TABLE 146. NORTH AMERICA DOXORUBICIN MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 147. NORTH AMERICA DOXORUBICIN MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 148. NORTH AMERICA DOXORUBICIN MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 149. NORTH AMERICA DOXORUBICIN MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 150. NORTH AMERICA DOXORUBICIN MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 151. NORTH AMERICA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 152. LATIN AMERICA DOXORUBICIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 153. LATIN AMERICA DOXORUBICIN MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 154. LATIN AMERICA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2017-2032 (USD MILLION)
TABLE 155. LATIN AMERICA DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2017-2032 (USD MILLION)
TABLE 156. LATIN AMERICA DOXORUBICIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 157. LATIN AMERICA DOXORUBICIN MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 158. LATIN AMERICA DOXORUBICIN MARKET SIZE, BY DOSAGE STRENGTH, 2017-2032 (USD MILLION)
TABLE 159. LATIN AMERICA DOXORUBICIN MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 160. LATIN AMERICA DOXORUBICIN MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 161. LATIN AMERICA DOXORUBICIN MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 162. LATIN AMERICA DOXORUBICIN MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 163. LATIN AMERICA DOXORUBICIN MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 164. LATIN AMERICA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 165. AFRICA DOXORUBICIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 166. AFRICA DOXORUBICIN MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 167. AFRICA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2017-2032 (USD MILLION)
TABLE 168. AFRICA DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2017-2032 (USD MILLION)
TABLE 169. AFRICA DOXORUBICIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 170. AFRICA DOXORUBICIN MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 171. AFRICA DOXORUBICIN MARKET SIZE, BY DOSAGE STRENGTH, 2017-2032 (USD MILLION)
TABLE 172. AFRICA DOXORUBICIN MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 173. AFRICA DOXORUBICIN MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 174. AFRICA DOXORUBICIN MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 175. AFRICA DOXORUBICIN MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 176. AFRICA DOXORUBICIN MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 177. AFRICA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 178. MIDDLE EAST DOXORUBICIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 179. MIDDLE EAST DOXORUBICIN MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 180. MIDDLE EAST DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2017-2032 (USD MILLION)
TABLE 181. MIDDLE EAST DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2017-2032 (USD MILLION)
TABLE 182. MIDDLE EAST DOXORUBICIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 183. MIDDLE EAST DOXORUBICIN MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 184. MIDDLE EAST DOXORUBICIN MARKET SIZE, BY DOSAGE STRENGTH, 2017-2032 (USD MILLION)
TABLE 185. MIDDLE EAST DOXORUBICIN MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 186. MIDDLE EAST DOXORUBICIN MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 187. MIDDLE EAST DOXORUBICIN MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 188. MIDDLE EAST DOXORUBICIN MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 189. MIDDLE EAST DOXORUBICIN MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 190. MIDDLE EAST DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 191. GLOBAL DOXORUBICIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 192. NATO DOXORUBICIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 193. NATO DOXORUBICIN MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 194. NATO DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2017-2032 (USD MILLION)
TABLE 195. NATO DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2017-2032 (USD MILLION)
TABLE 196. NATO DOXORUBICIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 197. NATO DOXORUBICIN MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 198. NATO DOXORUBICIN MARKET SIZE, BY DOSAGE STRENGTH, 2017-2032 (USD MILLION)
TABLE 199. NATO DOXORUBICIN MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 200. NATO DOXORUBICIN MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 201. NATO DOXORUBICIN MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 202. NATO DOXORUBICIN MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 203. NATO DOXORUBICIN MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 204. NATO DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 205. G7 DOXORUBICIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 206. G7 DOXORUBICIN MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 207. G7 DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2017-2032 (USD MILLION)
TABLE 208. G7 DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2017-2032 (USD MILLION)
TABLE 209. G7 DOXORUBICIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 210. G7 DOXORUBICIN MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 211. G7 DOXORUBICIN MARKET SIZE, BY DOSAGE STRENGTH, 2017-2032 (USD MILLION)
TABLE 212. G7 DOXORUBICIN MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 213. G7 DOXORUBICIN MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 214. G7 DOXORUBICIN MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 215. G7 DOXORUBICIN MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 216. G7 DOXORUBICIN MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 217. G7 DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 218. BRICS DOXORUBICIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 219. BRICS DOXORUBICIN MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 220. BRICS DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2017-2032 (USD MILLION)
TABLE 221. BRICS DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2017-2032 (USD MILLION)
TABLE 222. BRICS DOXORUBICIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 223. BRICS DOXORUBICIN MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 224. BRICS DOXORUBICIN MARKET SIZE, BY DOSAGE STRENGTH, 2017-2032 (USD MILLION)
TABLE 225. BRICS DOXORUBICIN MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 226. BRICS DOXORUBICIN MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 227. BRICS DOXORUBICIN MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 228. BRICS DOXORUBICIN MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 229. BRICS DOXORUBICIN MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 230. BRICS DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 231. EUROPEAN UNION DOXORUBICIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 232. EUROPEAN UNION DOXORUBICIN MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2017-2032 (USD MILLION)
TABLE 234. EUROPEAN UNION DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2017-2032 (USD MILLION)
TABLE 235. EUROPEAN UNION DOXORUBICIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION DOXORUBICIN MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION DOXORUBICIN MARKET SIZE, BY DOSAGE STRENGTH, 2017-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION DOXORUBICIN MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION DOXORUBICIN MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 240. EUROPEAN UNION DOXORUBICIN MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 241. EUROPEAN UNION DOXORUBICIN MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION DOXORUBICIN MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 243. EUROPEAN UNION DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 244. ASEAN DOXORUBICIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 245. ASEAN DOXORUBICIN MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 246. ASEAN DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2017-2032 (USD MILLION)
TABLE 247. ASEAN DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2017-2032 (USD MILLION)
TABLE 248. ASEAN DOXORUBICIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 249. ASEAN DOXORUBICIN MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 250. ASEAN DOXORUBICIN MARKET SIZE, BY DOSAGE STRENGTH, 2017-2032 (USD MILLION)
TABLE 251. ASEAN DOXORUBICIN MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 252. ASEAN DOXORUBICIN MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 253. ASEAN DOXORUBICIN MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 254. ASEAN DOXORUBICIN MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 255. ASEAN DOXORUBICIN MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 256. ASEAN DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 257. GCC DOXORUBICIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 258. GCC DOXORUBICIN MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 259. GCC DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2017-2032 (USD MILLION)
TABLE 260. GCC DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2017-2032 (USD MILLION)
TABLE 261. GCC DOXORUBICIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 262. GCC DOXORUBICIN MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 263. GCC DOXORUBICIN MARKET SIZE, BY DOSAGE STRENGTH, 2017-2032 (USD MILLION)
TABLE 264. GCC DOXORUBICIN MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 265. GCC DOXORUBICIN MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 266. GCC DOXORUBICIN MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 267. GCC DOXORUBICIN MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 268. GCC DOXORUBICIN MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 269. GCC DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 270. GLOBAL DOXORUBICIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 271. CHINA DOXORUBICIN MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 272. CHINA DOXORUBICIN MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 273. CHINA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2017-2032 (USD MILLION)
TABLE 274. CHINA DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2017-2032 (USD MILLION)
TABLE 275. CHINA DOXORUBICIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 276. CHINA DOXORUBICIN MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 277. CHINA DOXORUBICIN MARKET SIZE, BY DOSAGE STRENGTH, 2017-2032 (USD MILLION)
TABLE 278. CHINA DOXORUBICIN MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 279. CHINA DOXORUBICIN MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 280. CHINA DOXORUBICIN MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 281. CHINA DOXORUBICIN MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 282. CHINA DOXORUBICIN MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 283. CHINA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 284. UNITED STATES DOXORUBICIN MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 285. UNITED STATES DOXORUBICIN MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 286. UNITED STATES DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2017-2032 (USD MILLION)
TABLE 287. UNITED STATES DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2017-2032 (USD MILLION)
TABLE 288. UNITED STATES DOXORUBICIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 289. UNITED STATES DOXORUBICIN MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 290. UNITED STATES DOXORUBICIN MARKET SIZE, BY DOSAGE STRENGTH, 2017-2032 (USD MILLION)
TABLE 291. UNITED STATES DOXORUBICIN MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 292. UNITED STATES DOXORUBICIN MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 293. UNITED STATES DOXORUBICIN MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 294. UNITED STATES DOXORUBICIN MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 295. UNITED STATES DOXORUBICIN MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 296. UNITED STATES DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 297. JAPAN DOXORUBICIN MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 298. JAPAN DOXORUBICIN MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 299. JAPAN DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2017-2032 (USD MILLION)
TABLE 300. JAPAN DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2017-2032 (USD MILLION)
TABLE 301. JAPAN DOXORUBICIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 302. JAPAN DOXORUBICIN MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 303. JAPAN DOXORUBICIN MARKET SIZE, BY DOSAGE STRENGTH, 2017-2032 (USD MILLION)
TABLE 304. JAPAN DOXORUBICIN MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 305. JAPAN DOXORUBICIN MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 306. JAPAN DOXORUBICIN MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 307. JAPAN DOXORUBICIN MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 308. JAPAN DOXORUBICIN MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 309. JAPAN DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 310. INDIA DOXORUBICIN MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 311. INDIA DOXORUBICIN MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 312. INDIA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2017-2032 (USD MILLION)
TABLE 313. INDIA DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2017-2032 (USD MILLION)
TABLE 314. INDIA DOXORUBICIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 315. INDIA DOXORUBICIN MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 316. INDIA DOXORUBICIN MARKET SIZE, BY DOSAGE STRENGTH, 2017-2032 (USD MILLION)
TABLE 317. INDIA DOXORUBICIN MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 318. INDIA DOXORUBICIN MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 319. INDIA DOXORUBICIN MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 320. INDIA DOXORUBICIN MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 321. INDIA DOXORUBICIN MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 322. INDIA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 323. GERMANY DOXORUBICIN MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 324. GERMANY DOXORUBICIN MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 325. GERMANY DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2017-2032 (USD MILLION)
TABLE 326. GERMANY DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2017-2032 (USD MILLION)
TABLE 327. GERMANY DOXORUBICIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 328. GERMANY DOXORUBICIN MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 329. GERMANY DOXORUBICIN MARKET SIZE, BY DOSAGE STRENGTH, 2017-2032 (USD MILLION)
TABLE 330. GERMANY DOXORUBICIN MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 331. GERMANY DOXORUBICIN MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 332. GERMANY DOXORUBICIN MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 333. GERMANY DOXORUBICIN MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 334. GERMANY DOXORUBICIN MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 335. GERMANY DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 336. UNITED KINGDOM DOXORUBICIN MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 337. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 338. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2017-2032 (USD MILLION)
TABLE 339. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2017-2032 (USD MILLION)
TABLE 340. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 341. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 342. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY DOSAGE STRENGTH, 2017-2032 (USD MILLION)
TABLE 343. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 344. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 345. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 346. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 347. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 348. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 349. AUSTRALIA DOXORUBICIN MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 350. AUSTRALIA DOXORUBICIN MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 351. AUSTRALIA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2017-2032 (USD MILLION)
TABLE 352. AUSTRALIA DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2017-2032 (USD MILLION)
TABLE 353. AUSTRALIA DOXORUBICIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 354. AUSTRALIA DOXORUBICIN MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 355. AUSTRALIA DOXORUBICIN MARKET SIZE, BY DOSAGE STRENGTH, 2017-2032 (USD MILLION)
TABLE 356. AUSTRALIA DOXORUBICIN MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 357. AUSTRALIA DOXORUBICIN MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 358. AUSTRALIA DOXORUBICIN MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 359. AUSTRALIA DOXORUBICIN MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 360. AUSTRALIA DOXORUBICIN MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 361. AUSTRALIA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 362. FRANCE DOXORUBICIN MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 363. FRANCE DOXORUBICIN MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 364. FRANCE DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2017-2032 (USD MILLION)
TABLE 365. FRANCE DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2017-2032 (USD MILLION)
TABLE 366. FRANCE DOXORUBICIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 367. FRANCE DOXORUBICIN MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 368. FRANCE DOXORUBICIN MARKET SIZE, BY DOSAGE STRENGTH, 2017-2032 (USD MILLION)
TABLE 369. FRANCE DOXORUBICIN MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 370. FRANCE DOXORUBICIN MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 371. FRANCE DOXORUBICIN MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 372. FRANCE DOXORUBICIN MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 373. FRANCE DOXORUBICIN MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 374. FRANCE DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 375. SOUTH KOREA DOXORUBICIN MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 376. SOUTH KOREA DOXORUBICIN MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 377. SOUTH KOREA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2017-2032 (USD MILLION)
TABLE 378. SOUTH KOREA DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2017-2032 (USD MILLION)
TABLE 379. SOUTH KOREA DOXORUBICIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 380. SOUTH KOREA DOXORUBICIN MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 381. SOUTH KOREA DOXORUBICIN MARKET SIZE, BY DOSAGE STRENGTH, 2017-2032 (USD MILLION)
TABLE 382. SOUTH KOREA DOXORUBICIN MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 383. SOUTH KOREA DOXORUBICIN MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 384. SOUTH KOREA DOXORUBICIN MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 385. SOUTH KOREA DOXORUBICIN MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 386. SOUTH KOREA DOXORUBICIN MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 387. SOUTH KOREA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 388. ITALY DOXORUBICIN MARKET SIZE, 2017-2032 (USD MILLION)

Companies Mentioned

  • Apotex Inc.
  • Baxter International Inc.
  • Cadila Pharmaceuticals Ltd.
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Fresenius Kabi AG
  • Getwell Oncology Pvt Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services Inc.
  • Manus Aktteva Biopharma LLP
  • Meiji Holdings Co., Ltd.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • TTY Biopharma Company Limited

Table Information

Report AttributeDetails
No. of Pages187
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.17 Billion
Forecasted Market Value ( USD ) by 2032 $ 1.69 Billion
Compound Annual Growth Rate6.3%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

Doxorubicin - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Doxorubicin - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 130 Pages
  • Global
From
Liposomal Doxorubicin Market Report by Product, Application, and Region 2026-2034 - Product Image

Liposomal Doxorubicin Market Report by Product, Application, and Region 2026-2034

  • Report
  • 141 Pages
  • Global
From
Liposomal Doxorubicin Market Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025-2030 - Product Image

Liposomal Doxorubicin Market Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025-2030

  • Report
  • 89 Pages
  • Global
From
Liposomal Doxorubicin Market Report 2026 - Product Image

Liposomal Doxorubicin Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Doxorubicin Market Report by Application, Distribution Channel, and Region 2026-2034 - Product Image

Doxorubicin Market Report by Application, Distribution Channel, and Region 2026-2034

  • Report
  • 137 Pages
  • Global
From

About the Doxorubicin Market

Doxorubicin is an oncology drug used to treat a variety of cancers, including leukemia, lymphoma, and breast, ovarian, and bladder cancer. It is a type of anthracycline antibiotic, derived from Streptomyces peucetius, and works by interfering with the growth of cancer cells. It is administered intravenously, and is often used in combination with other drugs. Doxorubicin is one of the most widely used chemotherapy drugs, and is often used in combination with other drugs to treat a variety of cancers. It is also used to treat Kaposi's sarcoma, a type of skin cancer. Side effects of doxorubicin include nausea, vomiting, hair loss, and an increased risk of infection. The doxorubicin market is highly competitive, with many companies offering generic versions of the drug. Some of the major players in the market include Pfizer, Novartis, Merck, Bristol-Myers Squibb, and AstraZeneca. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.